

### **Amendments to the Claims:**

Claim 1 (original) A pharmaceutical composition comprising an alpha-adrenoceptor antagonist, a 5-HT<sub>4</sub>-receptor antagonist and a pharmaceutically acceptable carrier.

Claim 2 (original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is non-selective.

Claim 3 (original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selective for the alpha<sub>1</sub>-receptor.

Claim 4 (original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selected from abanoquil, alfuzosin, indoramin, tamsulosin, doxazosin, parvosin, terazosin, abanoquil, prazosin and pharmaceutically acceptable salts thereof.

Claim 5 (currently amended) A pharmaceutical compositions as claimed in ~~any of~~ claims 1 to 4 wherein the 5-HT<sub>4</sub>-receptor antagonist is selective for the 5-HT<sub>4</sub>-receptor.

Claim 6 (currently amended) A pharmaceutical composition as claimed in ~~any of~~ claims 1 to 4 wherein the 5-HT<sub>4</sub>-receptor antagonist is selected from SB 205800, SB 203186, R50595, GR 113808, GR 125487, GR 138897, LY-353433, DAU 6285, SDZ 205-557, RS 23597-190, or (3S-trans)-4-(4-[[[(8-chloro-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin-1-yl)-butyric acid and pharmaceutically acceptable salts thereof.

Claim 7 (original) A pharmaceutical composition as claimed in claim 6 wherein the 5-HT<sub>4</sub>-receptor antagonist is (3S-trans)-4-(4-[[[(8-chloro-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin-1-yl)-butyric acid and pharmaceutically acceptable salts thereof.

Claim 8 (canceled) An alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist for use as a medicament.

Claim 9 (canceled) Use of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms.

Claim 10 (canceled) Use of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with overactive bladder.

Claim 11 (canceled) Use of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with mild to moderate benign prostatic hyperplasia in mammals.

Claim 12 (original) A product comprising a first pharmaceutically acceptable composition containing an alpha-adrenoceptor antagonist and a second pharmaceutically acceptable composition a 5-HT<sub>4</sub>-receptor antagonist for use as a combined preparation for simultaneous or sequential use in treating the lower urinary tract symptoms associated with overactive

Claim 13 (new) A method for treating lower urinary tract symptoms comprising administering to a host in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist.

Claim 14 (new) A method for treating lower urinary tract symptoms associated with overactive bladder comprising administering to a host in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist.

Claim 15 (new) A method for treating the lower urinary tract symptoms associated with mild to moderate benign prostrate hyperplasia in mammals comprising administering to a mammal in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT<sub>4</sub>-receptor antagonist